Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1401Neoplasms 1128Prostatic Neoplasms 745Lung Neoplasms 621Colorectal Neoplasms 599Carcinoma, Non-Small-Cell Lung 570Carcinoma, Hepatocellular 414Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 356Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 310Head and Neck Neoplasms 290Neoplasm Metastasis 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 254Uterine Cervical Neoplasms 248Recurrence 248Melanoma 243Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 214Sarcoma 209Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 182

Interventions

lipoarabinomannan 1atezolizumab 1Lamivudine 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER × Extensive Stage Lung Small Cell Carcinoma × Clear all
NCT04696575 2025-12-15

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Recruiting
28 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡